Core Viewpoint - The recent disclosure of the third-quarter reports of A-share listed companies reveals significant movements of institutional investors, particularly the entry of pension funds into various stocks, indicating potential investment opportunities in these companies [1]. Group 1: Pension Fund Holdings - Pension funds have newly entered the top ten circulating shareholder lists of 20 companies in the third quarter [1]. - Ding Tong Technology has the highest number of new pension fund holdings, with 2 institutions [1]. - Other companies with 1 new pension fund holding each include Beifang Copper, Haiyou Engineering, Aibisen, Hubei Yihua, Donghua Testing, Shenghui Integration, Jingzhu Technology, Shenghong Co., Tongfei Co., Haiyou Development, Hanzhong Precision, Zhongtie Assembly, Henghui Security, Zhidemai, Kain Technology, Ketao Biology, Runben Co., Jieya Co., and Rejing Biology [1]. Group 2: Company-Specific Insights - **Ding Tong Technology**: - New pension fund holdings valued at 144 million yuan - Q3 revenue of 372 million yuan, up 48.12% YoY - Net profit of 61.175 million yuan, up 110.67% YoY [4]. - **Beifang Copper**: - New pension fund holdings valued at 162 million yuan - Q3 revenue of 7.162 billion yuan, up 24.14% YoY - Net profit of 202 million yuan, up 133.57% YoY [3]. - **Haiyou Engineering**: - New pension fund holdings valued at 66 million yuan - Q3 revenue of 1.243 billion yuan [2]. - **Aibisen**: - New pension fund holdings valued at 19 million yuan - Q3 revenue of 115.56 million yuan [2]. - **Hubei Yihua**: - New pension fund holdings valued at 102 million yuan - Q3 revenue of 695.46 million yuan [2]. - **Rejing Biology**: - New pension fund holdings valued at 255 million yuan - Q3 revenue of 310 million yuan, down 19.8% YoY - Net loss of 109 million yuan, compared to a loss of 40.64 million yuan in the same period last year [2][4].

Core Viewpoint - Beijing Hotgen Biotech Co., Ltd. announced that its affiliate, ShunJing Biopharmaceutical Technology Co., Ltd., has achieved positive preliminary results in the Phase Ib clinical trial of the innovative drug SGC001, which is aimed at treating acute myocardial infarction [1][2]. Clinical Progress - The Phase Ib clinical trial of SGC001 has been completed, showing good safety and tolerability in patients with anterior ST-segment elevation myocardial infarction (STEMI) [1]. - No grade 3 or higher adverse events were reported across low (300 mg), medium (600 mg), and high (900 mg) dosage groups, indicating a strong safety profile [1][2]. - Pharmacokinetic analysis revealed that the median Tmax for SGC001 ranged from 1.30 to 4.07 hours, with a half-life (t1/2) of approximately 8 to 11 days [2]. Preliminary Efficacy Results - Initial efficacy results indicated that SGC001 at 600 mg and 900 mg doses showed a trend towards myocardial protection compared to the placebo group, with median reductions in myocardial infarction area percentages of 20.5% and 38.1%, respectively [2]. - The time required for high-sensitivity cardiac troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels was shorter in the treatment groups compared to the placebo [2]. Drug Overview - SGC001 is a monoclonal antibody developed for emergency treatment of acute myocardial infarction, specifically targeting anterior STEMI [3]. - The drug has received clinical trial approvals from both the U.S. FDA and China's National Medical Products Administration (NMPA), and it was granted Fast Track Designation by the FDA in March 2025 [3]. - The project has also received support from Beijing's Science and Technology Program and is recognized as an innovative pharmaceutical product [3].

（文章来源：证券日报） 证券日报网讯 10月22日晚间，热景生物发布公告称，近日，公司收到参股公司北京舜景生物医药技术 有限公司关于自主研制的创新药SGC001注射液Ib期临床研究获得了积极的初步结果的汇报。 ...

Group 1 - Sanwang Communication plans to repurchase shares worth 20-40 million yuan for employee stock incentive plans [1] - Ankrui reported a net profit of 192 million yuan for the first three quarters, a year-on-year increase of 21.31% [1] - Taishan Petroleum's net profit for the first three quarters reached 113 million yuan, up 112.32% year-on-year [1] - Zhejiang Xiantong achieved a net profit of 152 million yuan for the first three quarters, a 17.4% increase year-on-year [1] Group 2 - Xuanji Information reported a net loss of 173 million yuan for the first three quarters [1] - Mailande's net profit slightly decreased by 0.07% to 96 million yuan for the first three quarters [1] - Tengjing Technology's subsidiary received a sales order worth 87.61 million yuan [1] Group 3 - Hotgen Biotech's affiliate achieved positive results in Phase Ib clinical trials for the innovative drug SGC001 [1] - Zhongyan Dadi won a bid for a sports project in Beijing worth 74.04 million yuan [1] - Henghui Security's net profit decreased by 12.85% to 81.98 million yuan for the first three quarters [1] Group 4 - Xiongdi Technology's net profit increased by 71.16% to 18.38 million yuan for the first three quarters [1] - Meilixin reported a net loss of 215 million yuan for the first three quarters [1] - Haichen Pharmaceutical's net profit grew by 16.22% to 32.68 million yuan for the first three quarters [1] Group 5 - Qiaoyuan Co. reported a net profit of 181 million yuan for the first three quarters, a 40.54% increase year-on-year [1] - Fuda Co. achieved a net profit of 221 million yuan for the first three quarters, up 83.27% year-on-year [1] - Xianggang Technology's net profit surged by 186.19% to 95.47 million yuan for the first three quarters [1] Group 6 - ST Nanchuan received a restriction order from the court due to a financial dispute [1] - Changyou Technology announced the dismissal of two vice presidents [1] - Haoyuan Automotive received a project confirmation for an automatic parking system worth 576 million yuan [1] Group 7 - Jiuzhou Biotech obtained a medical device registration certificate for a diagnostic kit [1] - Shihua Machinery signed an investment intention letter for a subsidiary's capital increase [1] - Zhuhai Mian Group plans to transfer 100% equity of Gree Real Estate [1] Group 8 - Dalian Heavy Industry reported a net profit of 490 million yuan for the first three quarters, a 23.97% increase year-on-year [1] - Haimeng Data reported a net loss of 75.43 million yuan for the first three quarters [1] - Feilong Co. achieved a net profit of 287 million yuan for the first three quarters, a 7.54% increase year-on-year [1] Group 9 - Kaipu Testing reported a net profit of 57.84 million yuan for the first three quarters, a 3.34% increase year-on-year [1] - Ganyue Express signed a strategic cooperation agreement with a major energy company [1] - Tuoshan Heavy Industry's controlling shareholder plans to reduce its stake by 2.82% [1] Group 10 - Yiatong's shareholder plans to reduce its stake by 1% [1] - Weishi Electronics reported a net profit of 24.29 million yuan for the first three quarters, a 22.59% decrease year-on-year [1] - Shensi Electronics won a bid for a data space construction project worth 161 million yuan [1] Group 11 - Xiechuang Data plans to purchase server assets worth up to 4 billion yuan [1] - Shandong Express's controlling shareholder plans to transfer 7% of its shares [1] - ST Huapeng's subsidiary received a government subsidy of 4.65 million yuan [1] Group 12 - Jieqiang Equipment's shareholder plans to reduce its stake by 1% [1] - China Jushi reported a net profit of 2.568 billion yuan for the first three quarters, a 67.51% increase year-on-year [1] - ST Fanli reported a net loss of 44.78 million yuan for the first three quarters [1] Group 13 - Xiyu Tourism reported a net profit of 98.58 million yuan for the first three quarters, a 14.51% decrease year-on-year [1] - Abison reported a net profit of 185 million yuan for the first three quarters, a 57.33% increase year-on-year [1] - Huayan Precision reported a net profit of 70.76 million yuan for the first three quarters, a 31.07% increase year-on-year [1] Group 14 - Jiangling Motors reported a net profit of 74.9 million yuan for the first three quarters, a 35.76% decrease year-on-year [1]

智通财经APP讯，热景生物(688068.SH)发布公告，近日，公司收到参股公司北京舜景生物医药技术有 限公司(简称"舜景医药")关于自主研制的创新药SGC001注射液Ib期临床研究获得了积极的初步结果的汇 报。 初步有效性结果显示：在中国前壁ST段抬高型心肌梗死且接受经皮冠状动脉介入(PCI)治疗的患者中， SGC001在600mg和900mg剂量组较安慰剂组在心肌保护方面均有有效趋势，表现为心肌梗死面积百分比 (IS%)减少，高敏肌钙蛋白I(hsTnI)和高敏C反应蛋白(hs-CRP)回复至正常水平所需时间更短;与安慰剂组 相比，有随着剂量增加疗效增加的趋势，中高剂量组心肌梗死面积百分比中位数分别降低20.5%和 38.1%。该项目后续将继续按照临床试验方案开展临床工作。 ...

Core Viewpoint - The announcement from Hotgen Biotech (688068.SH) indicates that its affiliate, Beijing ShunJing Biopharmaceutical Technology Co., Ltd., has reported positive preliminary results from the Phase Ib clinical trial of its innovative drug SGC001 injection for treating ST-segment elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) [1] Group 1 - The preliminary efficacy results show that SGC001 at doses of 600mg and 900mg demonstrated a significant trend in myocardial protection compared to the placebo group, evidenced by a reduction in myocardial infarction area percentage (IS%) [1] - The median reduction in myocardial infarction area percentage for the mid-high dose groups was 20.5% and 38.1%, respectively, indicating a dose-dependent increase in efficacy [1] - The time required for high-sensitivity troponin I (hsTnI) and high-sensitivity C-reactive protein (hs-CRP) to return to normal levels was shorter in the treatment groups compared to the placebo group [1] Group 2 - The project will continue to follow the clinical trial protocol for further clinical work [1]

热景生物公告，近日收到参股公司北京舜景生物医药技术有限公司关于自主研制的创新药SGC001注射 液Ib期临床研究获得了积极的初步结果的汇报。具体数据显示，在前壁ST段抬高型心肌梗死患者中， SGC001在600 mg和900 mg剂量组较安慰剂组在心肌保护方面均有有效趋势，心肌梗死面积百分比中位 数分别降低20.5%和38.1%。SGC001注射液在前壁ST段抬高型心肌梗死患者人群中安全耐受性良好，未 发生3级及3级以上不良事件和严重不良事件。 ...

Group 1 - Mindray Medical received the highest number of institutional surveys, with 184 institutions participating, including 14 fund companies, 8 securities companies, 7 private equity firms, 7 insurance companies, and 124 overseas institutions [1] - The company aims to enhance its international influence, align with its global development strategy, attract talent, and optimize shareholder structure and liquidity through its overseas listing [1] - Mindray expects a year-on-year revenue growth by Q3 2025, with a trend of quarterly improvement in revenue, particularly in international markets, which are anticipated to accelerate growth starting from Q3 [1] Group 2 - Rongbai Technology has made significant progress in developing overseas clients, including major companies like Panasonic, and has a robust overseas customer structure [2] - Dike Co. announced a cash acquisition of 62.5% of Jiangsu Jinkai Semiconductor Technology Co., which will become a subsidiary and contribute to the company's consolidated financial statements [2] - Jiangsu Jinkai focuses on storage chip packaging and testing services, with a current capacity of 3KK/month for packaging and 2.5KK/month for testing, planning to expand to 4KK/month [2] Group 3 - Huicheng Environmental has seen a dramatic increase in stock price, nearly 30 times since its low in 2022, with a recent weekly increase of over 20% [3] - The company successfully launched its 20,000 tons/year mixed waste plastic resource utilization project, with stable production following technical upgrades [3] - Jiao Cheng Ultrasonic is increasing its market share in the semiconductor packaging sector by leveraging its technology to compete against foreign equipment manufacturers [3] Group 4 - Hotgen Biotech's affiliate, ShunJing Pharmaceutical, is progressing well with its innovative drug SGC001, having completed Phase I clinical trials and preparing to initiate Phase II trials [4] - Initial results from the trials indicate that the drug's efficacy aligns with expectations, with further statistical analysis underway [4]

Policy Developments - The National Healthcare Security Administration (NHSA) announced the preliminary results of the review for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, receiving 75 feedback comments during the public consultation period [1] - A total of 718 submissions were received for the basic medical insurance directory, with 535 passing the formal review, including 311 from outside the directory and 224 from within [2] - The review results showed changes for 6 drugs, with some being approved and others not, indicating a rigorous review process for drug inclusion [1][2] Drug and Device Approvals - Rejuve Bio announced the completion of Phase Ib clinical trials for its innovative drug SGC001 injection, showing no severe adverse events and preliminary efficacy results aligning with expectations [3] - Sanyou Medical's subsidiary received a Class III medical device registration certificate for a bone filling pouch, designed for use in vertebroplasty procedures [4] Financial Reports - Mindray Medical reported a 32.96% year-on-year decline in net profit for the first half of 2025, with revenues of 16.743 billion yuan [5] - Shanghai Pharmaceuticals achieved a 51.56% increase in net profit year-on-year, with revenues of 141.593 billion yuan [6] - Baiyang Pharmaceutical reported a revenue of 3.751 billion yuan for the first half of 2025, with a focus on innovative drugs and devices, and a brand revenue of 2.716 billion yuan [7] - Seli Medical reported a net loss of 56.1192 million yuan for the first half of 2025, with revenues declining by 40.20% [8] Capital Market Activities - Kangtuo Medical plans to acquire a 55.5% stake in Rongyu Biological and a 72.9931% stake in Xi'an Huicai for 84.9825 million yuan, aiming to consolidate its holdings [9] - Sitai Medical intends to transfer a 9.87% stake in Ranno Pharmaceutical for 66.4416 million yuan [10] Industry Developments - A new method developed by Karolinska Institute and other research institutions may enable early detection and prevention of Type 1 diabetes [11] - A clinical trial successfully demonstrated the use of a brain-machine interface for precise tumor boundary localization during surgery, marking a significant advancement in neurosurgery technology [12][13] Public Opinion Alerts - Dongfang Biological announced the resignation of board member Fang Xincheng due to personal reasons [14]

Core Viewpoint - The announcement highlights the successful completion of Phase Ia and Ib clinical trials for the innovative drug SGC001 injection by the affiliated company ShunJing Pharmaceutical, indicating promising results for acute myocardial infarction treatment [1] Group 1: Clinical Trial Results - SGC001 injection has completed Phase Ia clinical research in healthy volunteers and Phase Ib clinical observation in patients with ST-segment elevation myocardial infarction [1] - No grade 3 or higher adverse events were reported across all dosage groups, suggesting a favorable safety profile [1] - Preliminary efficacy results align with expectations, indicating potential effectiveness for acute myocardial infarction patients [1] Group 2: Market Context - There are currently no antibody drugs for acute myocardial infarction that have entered clinical research or approval stages, positioning SGC001 as a potentially pioneering treatment in this area [1]